Stocks in play: Oncolytics Biotech Inc
Announces the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium, to be held at the Henry B. González Convention Center in San Antonio, Texas from December 6 – 10, 2022. One will feature interim results from a bridging clinical trial being conducted by Oncolytics' partner, Adlai Nortye, to evaluate pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic HR+/HER2- breast cancer. The second poster, in collaboration with SOLTI-Innovative Cancer Research, will include data from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients. Oncolytics Biotech Inc shares T.ONC are trading -$0.11 at $1.88.
Read:
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
New Biotech Sector Drug Combinations Target a Drop in Pancreatic Cancer Mortality Rates
Highly Sought After Natural Ingredients Appearing in More Plant-Based Products Across North America
Fresher, Healthier Food Options Coming Soon to an Airplane Tray Near You
Airline Industry Wooing Back Customers with Enhanced, Healthier Menu Options